CIViC Compass
Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.

CIViC Evidence Items

144 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline
BClinical — prospective trial or retrospective cohort study
CCase study — single case report or small case series
DPreclinical — in vitro or animal model data
EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

PredictiveDiagnosticPrognosticFunctionalPredispos.Oncogenic
BCR::ABL132311
BRAF18642621
EGFR2481232
EML4::ALK64
ERBB21422
FLT355221
KIT10237
KRAS1594244
PIK3CA156164
PTEN5313121
TP5352401002
VHL52363515
Predictive:Links a variant to treatment response or resistance
Diagnostic:Supports or refutes a specific disease diagnosis
Prognostic:Informs disease progression or clinical outcome
Functional:Characterises the biological effect of a variant
Predisposing:Germline variant associated with cancer predisposition
Oncogenic:Characterises the variant's role in oncogenesis
Clear
LevelGeneVariantTypeDirectionSignificanceDiseaseDrugsSource
BERBB2MutationPredictiveSupportsSensitivity/ResponseBreast CancerNeratinibMa et al., 2017
BERBB2OverexpressionPredictiveDoes Not SupportSensitivity/ResponsePancreatic CancerTrastuzumab,CapecitabineHarder et al., 2012
BERBB2OverexpressionPredictiveDoes Not SupportSensitivity/ResponsePancreatic CancerGemcitabine,TrastuzumabSafran et al., 2004
BERBB2AmplificationPredictiveSupportsSensitivity/ResponseColorectal CancerTrastuzumab,PertuzumabHainsworth et al., 2018
AERBB2MutationPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaTrastuzumab DeruxtecanGoto et al., 2023
AERBB2G776delinsVCPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaTrastuzumab DeruxtecanGoto et al., 2023
AERBB2Y772_A775DUPPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaTrastuzumab DeruxtecanGoto et al., 2023
AERBB2Exon 20 InsertionPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaTrastuzumab DeruxtecanGoto et al., 2023
AERBB2MutationPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaZongertinibHeymach et al., 2025
AERBB2L755P OR ERBB2 G776V OR ERBB2 G776delinsVC OR ERBB2 P780_Y781insGSPPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaZongertinibHeymach et al., 2025
AERBB2A775_G776insYVMAPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaZongertinibHeymach et al., 2025
DERBB2AmplificationPredictiveSupportsSensitivity/ResponseBreast CancerAKTi-1/2She et al., 2008
BERBB2AmplificationPredictiveSupportsSensitivity/ResponseHer2-receptor Positive Breast CancerNeratinibBurstein et al., 2010
CERBB2Kinase Domain MutationPredictiveSupportsSensitivity/ResponseLung AdenocarcinomaAfatinibDe Grève et al., 2012
DERBB2Y772_A775DUPPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaAfatinib,SirolimusPerera et al., 2009
BERBB2AmplificationPredictiveSupportsSensitivity/ResponseHer2-receptor Positive Breast CancerAfatinibLin et al., 2012
BERBB2SERUM LEVELSPrognosticSupportsPoor OutcomeBreast CancerLee et al., 2016
DERBB2AmplificationPredictiveSupportsSensitivity/ResponseBreast CancerTrastuzumab,LapatinibXia et al., 2005
BERBB2AmplificationPredictiveSupportsSensitivity/ResponseHer2-receptor Positive Breast CancerAfatinibCortés et al., 2015
BERBB2AmplificationPredictiveSupportsSensitivity/ResponseHer2-receptor Positive Breast CancerAfatinib,TrastuzumabRing et al., 2015
BERBB2AmplificationPredictiveSupportsSensitivity/ResponseGastric AdenocarcinomaLapatinibSatoh et al., 2014
BERBB2AmplificationPredictiveDoes Not SupportSensitivity/ResponseLung Non-small Cell CarcinomaTrastuzumabLara et al., 2004
CERBB2G778_P780dupPredictiveSupportsSensitivity/ResponseLung AdenocarcinomaDacomitinibKris et al., 2015
CERBB2Y772_A775DUPPredictiveSupportsSensitivity/ResponseLung AdenocarcinomaTrastuzumab EmtansineWeiler et al., 2015
DERBB2AmplificationPredictiveSupportsSensitivity/ResponseHer2-receptor Positive Breast CancerPictilisibUtermark et al., 2012
DERBB2AmplificationPredictiveDoes Not SupportSensitivity/ResponseHer2-receptor Positive Breast CancerTgx 221Utermark et al., 2012
BERBB2AmplificationPredictiveSupportsSensitivity/ResponseHer2-receptor Positive Breast CancerTrastuzumab EmtansineHurvitz et al., 2013
CERBB2MutationPredictiveSupportsSensitivity/ResponseBladder CarcinomaPlatinum CompoundGroenendijk et al., 2016
CERBB2Y772_A775DUPPredictiveSupportsSensitivity/ResponseLung AdenocarcinomaAfatinibDe Grève et al., 2012
CERBB2G776LPredictiveSupportsSensitivity/ResponseLung AdenocarcinomaAfatinibDe Grève et al., 2012
CERBB2G778_P780dupPredictiveSupportsSensitivity/ResponseLung AdenocarcinomaAfatinibDe Grève et al., 2012
BERBB2AmplificationPredictiveDoes Not SupportSensitivity/ResponseLung Non-small Cell CarcinomaDacomitinibKris et al., 2015
CERBB2G778_P780dupPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaDacomitinibKris et al., 2015
CERBB2M774DELINSWLVPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaDacomitinibKris et al., 2015
BERBB2AmplificationPredictiveSupportsResistanceColorectal CancerCetuximabJeong et al., 2017
DERBB2AmplificationPredictiveSupportsSensitivity/ResponseBreast CancerPictilisibO'Brien et al., 2010
DERBB2L755SPredictiveSupportsResistanceCecum AdenocarcinomaCetuximabKavuri et al., 2015
CERBB2L755SPredictiveDoes Not SupportSensitivity/ResponseColorectal AdenocarcinomaLeucovorin,Trastuzumab,FluorouracilAung et al., 2016
BERBB2AmplificationPredictiveSupportsSensitivity/ResponseBladder CarcinomaTrastuzumab,PertuzumabHainsworth et al., 2018
CERBB2OverexpressionPredictiveSupportsSensitivity/ResponseSalivary Gland CancerZoledronic Acid,Capecitabine,TrastuzumabSharon et al., 2010
DERBB2T798IPredictiveDoes Not SupportSensitivity/ResponseBreast CancerOsimertinibHanker et al., 2017
BERBB2AmplificationPredictiveSupportsSensitivity/ResponseColorectal CancerPertuzumab,TrastuzumabMeric-Bernstam et al., 2019
CERBB2AmplificationPredictiveSupportsSensitivity/ResponseCholangiocarcinomaTrastuzumab,PertuzumabYarlagadda et al., 2019
BERBB2AmplificationPredictiveSupportsSensitivity/ResponseStomach CancerTrastuzumab DeruxtecanShitara et al., 2019
DERBB2AmplificationPredictiveSupportsSensitivity/ResponseColorectal CancerAfatinibLeto et al., 2015
BERBB2AmplificationPredictiveSupportsSensitivity/ResponseColorectal CancerTrastuzumab,PertuzumabGupta et al., 2022
BERBB2Mutation OR ERBB3 MutationPredictiveDoes Not SupportSensitivity/ResponseColorectal CancerPertuzumab,TrastuzumabGupta et al., 2022
BERBB2Activating MutationPredictiveDoes Not SupportSensitivity/ResponseCancerAfatinibBedard et al., 2022
CERBB2D769YPredictiveSupportsSensitivity/ResponseExtramammary Paget DiseaseAfatinibBedard et al., 2022
AERBB2S310FPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaTrastuzumab DeruxtecanGoto et al., 2023
Page 2 of 3
PreviousNext